Bcel stock forecast.
1 analysts 33.33% Hold 2 analysts 66.67% Sell 0 analysts 0% Strong Sell 0 analysts 0% Be the first to know when Wall Street analysts revise their BCEL stock forecasts and price …
Find the latest Atreca, Inc. (BCEL) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors. HOOK Stock 12 Months Forecast. $6.83. (1382.20% Upside) Based on 3 Wall Street analysts offering 12 month price targets for Hookipa Pharma in the last 3 months. The average price target is $6.83 with a high forecast of $7.00 and a low forecast of $6.50. The average price target represents a 1382.20% change from the last price of $0.46.In the world of business, cash flow is king. Having a clear understanding of your company’s cash flow is essential for making informed financial decisions and ensuring the long-term success of your business.BCEL Stock 12 Months Forecast. $2.00. (790.87% Upside) Based on 2 Wall Street analysts offering 12 month price targets for Atreca in the last 3 months. The average price target is $2.00 with a high forecast of $2.00 and a low forecast of $2.00. The average price target represents a 790.87% change from the last price of $0.22.Weather forecasts play an essential role in our daily lives, helping us plan our activities and stay prepared for any weather conditions that may come our way. One of the most common types of forecasts is the 7-day weather forecast, which p...
11.30% of Atreca stock is owned by insiders. Which Atreca insiders have been selling company stock? The following insiders have sold BCEL shares in the last 24 months: Bros. Advisors Lp Baker ($109,895.60), John A Orwin ($37,216.24), Phillips Courtney ($15,321.16), and Tito Serafini ($199,122.53).BCEL Stock 12 Months Forecast $2.00 (790.87% Upside) Based on 2 Wall Street analysts offering 12 month price targets for Atreca in the last 3 months. The average price target …BCEL Stock 12 Months Forecast $2.00 (790.87% Upside) Based on 2 Wall Street analysts offering 12 month price targets for Atreca in the last 3 months. The average price target …
Turning Spencer's outlook into concrete recommendations, Baird analyst Joel Beatty is pounding the table on two stocks that look especially compelling. According to the analyst, each name is ...Stock Price Forecast. The 8 analysts offering 12-month price forecasts for EyePoint Pharmaceuticals Inc have a median target of 28.00, with a high estimate of 55.00 and a low estimate of 20.00 ...
Penny stocks may sound like an interesting investment option, but there are some things that you should consider before deciding whether this is the right investment choice for you.5 equities research analysts have issued twelve-month target prices for Atreca's stock. Their BCEL share price targets range from $4.00 to $25.00. On average, they expect the company's stock price to reach $10.75 in the next twelve months. This suggests a possible upside of 4,474.5% from the stock's current price.Analyst projections state that BCEL is forecast to be at a low of $1.00 and a high of $9.00. In order for the stock price to hit the forecast high, the stock would need to plunge -3361.54% from its current level, while the stock would need to crash -284.62% from its current level to reach the projected low. Atreca Inc (BCEL) estimates and forecastsDec 1, 2023 · Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. Atreca Inc Cl A (BCEL) Company Description. Atreca Inc is a biopharmaceutical company utilizing its differentiated platform to discover and develop novel antibody-based immunotherapeutics to treat a range of solid tumor types. The company's product candidate, ATRC-101, is a monoclonal antibody in preclinical development with a novel mechanism ...
A treca, Inc. (BCEL) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock ...
Atreca Inc [BCEL] stock is trading at $0.22, up 8.95%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. ... An investor can expect a potential return of 1377.27% based on the average BCEL price forecast. Analyzing the BCEL fundamentals. In the same period, the company ...
Find real-time KR - Kroger Co stock quotes, company profile, news and forecasts from CNN Business.Stock Price Forecast. The 20 analysts offering 12-month price forecasts for Kroger Co have a median target of 51.75, with a high estimate of 65.00 and a low estimate of 37.00. The median estimate ...Nov 10, 2023 · The latest Atreca stock prices, stock quotes, news, and BCEL history to help you invest and trade smarter. ... The 11 analysts offering price forecasts for Atreca have a median target of 11.77 ... Performance Outlook. Short Term. 2W - 6W. Mid Term. 6W - 9M. Long Term. 9M+ Previous Close: 0.2197 ... Stock Falls 37%. Atreca (BCEL) suspends the development of only pipeline candidate, ATRC-101 ...Atreca, Inc. operates as a clinical-stage biopharmaceutical company, which engages in developing novel antibody-based therapeutics to treat a range of solid tumor types. Its technology leverages next-generation sequencing to identify the set of functional antibodies produced in patients during an immune response.April 06, 2023 — 09:55 am EDT. Written by Zacks Equity Research for Zacks ->. Shares of Atreca, Inc. (BCEL) have been struggling lately and have lost 20% over the past week. However, a hammer ...
Stock Price Forecast. The 4 analysts offering 12-month price forecasts for Heron Therapeutics Inc have a median target of 5.50, with a high estimate of 9.00 and a low estimate of 2.50. The median ...May 10, 2023 · On May 10, 2023, Atreca (NASDAQ:BCEL) announced its financial results for the first quarter of the year. The company reported Atreca Reports Q1 2023 Financial Results with Exceeding Analyst Estimates - Best Stocks Atreca, Inc. : Forcasts, revenue, earnings, analysts expectations, ratios for Atreca, Inc. Stock | BCEL | US04965G1094ENDRA Life Sciences Inc. 0.97. +0.01. +1.0417%. ARTH. Get Atreca Inc (BCEL:NASDAQ) real-time stock quotes, news, price and financial information from CNBC.Qifu Technology (NASDAQ:QFIN) pays an annual dividend of $0.98 per share and currently has a dividend yield of 6.10%. QFIN has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. The dividend payout ratio is 28.16%. This payout ratio is at a healthy, sustainable level, below 75%.
Stock Price Forecast. The 18 analysts offering 12-month price forecasts for Keurig Dr Pepper Inc have a median target of 37.00, with a high estimate of 42.00 and a low estimate of 27.00. The ...VKTX Stock 12 Months Forecast. $34.00. (187.40% Upside) Based on 6 Wall Street analysts offering 12 month price targets for Viking Therapeutics in the last 3 months. The average price target is $34.00 with a high forecast of $40.00 and a low forecast of $28.00. The average price target represents a 187.40% change from the last price of $11.83.
Wall Street Stock Market & Finance report, prediction for the future: You'll find the Century Aluminum share forecasts, stock quote and buy / sell signals below. According to present data Century Aluminum's CENX shares and potentially its market environment have been in a bullish cycle in the last 12 months (if exists).Find the latest Patterson-UTI Energy, Inc. (PTEN) stock quote, history, news and other vital information to help you with your stock trading and investing.Dec 1, 2023 · Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. Earnings Summary. For their last quarter, Atreca (BCEL) reported earnings of -$0.49 per share, beating the Zacks Consensus Estimate of $-0.56 per share. This reflects a positive earnings surprise ...The Wall Street analysts predict Outperform for BCEL. See at a glance whether NasdaqGS:BCEL will rise in the future. Company; Stock analysis; Earnings Calendars ... 4 years of reliable Atreca stock forecast. The Wall Street analysts predict Outperform for BCEL. See at a glance whether NasdaqGS:BCEL will rise in the future. …October 13, 2023. At the time of writing, Atreca Inc [BCEL] stock is trading at $0.38, up 61.06%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The BCEL shares have gain 66.93% over the last week, with a monthly amount glided 11.79%, and seem to be holding up well over a long-time horizon.Learn more about Atreca Inc's (BCEL) stock grades for Momentum, Growth and Estimate Revisions and determine whether this Biotechnology & Medical Research stock meets your investment needs. ... The Biotechnology and Medical Research sub-industry has a positive outlook, a historically defensive sub-industry. Drug sales are …9.19M. AMZN. 146.74. +0.02%. 21.10M. New. View today's Atreca Inc stock price and latest BCEL news and analysis. Create real-time notifications to follow any changes in the live stock price.
ATRECA, INC. stock price forecast for further price development down to -100.00% (time horizon: 1 day) and price target of 0.00 USD. Negative news sentiment. Short-term (time horizon: 2 weeks) ATRECA, INC. share price prediction for 2024-01-12 with daily closed price projections
NasdaqGS - NasdaqGS Real Time Price. Currency in USD. Find the latest Keurig Dr Pepper Inc. (KDP) stock quote, history, news and other vital information to help you with your stock trading and ...
BCELNASDAQ 0.2150USD −0.0047 −2.14% At close at Dec 1, 16:12 UTC-8 See on Supercharts Overview News Ideas Financials Technicals Forecast Price target 2.00R …Atreca is forecast to grow earnings and revenue by 10.3% and 9.5% per annum respectively while EPS is expected to grow by 30.2% per annum.VKTX Stock 12 Months Forecast. $34.00. (187.40% Upside) Based on 6 Wall Street analysts offering 12 month price targets for Viking Therapeutics in the last 3 months. The average price target is $34.00 with a high forecast of $40.00 and a low forecast of $28.00. The average price target represents a 187.40% change from the last price of $11.83.Earnings announcement* for BCEL: Our vendor, Zacks Investment Research, hasn't provided us with the upcoming earnings report date. BCEL has a "high" Earnings Quality Ranking (EQR) for the 5th ...How much is Atreca stock worth today? ( NASDAQ: BCEL) Atreca currently has 39,295,661 outstanding shares. With Atreca stock trading at $0.27 per share, the total value of Atreca stock (market capitalization) is $10.41M. Atreca stock was originally listed at a price of $18.05 in Jun 20, 2019.View Tecnoglass Inc TGLS investment & stock information. Get the latest Tecnoglass Inc TGLS detailed stock quotes, stock data, Real-Time ECN, charts, stats and more.Atreca, Inc. - Hold. Zacks' proprietary data indicates that Atreca, Inc. is currently rated as a Zacks Rank 3 and we are expecting an inline return from the BCEL shares relative to the market in ...Wall Street Stock Market & Finance report, prediction for the future: You'll find the Viking Therapeutics share forecasts, stock quote and buy / sell signals below. According to present data Viking Therapeutics's VKTX shares and potentially its market environment have been in a bullish cycle in the last 12 months (if exists).Penny stocks may sound like an interesting investment option, but there are some things that you should consider before deciding whether this is the right investment choice for you.Track Atreca Inc - Ordinary Shares - Class A (BCEL) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsNov 10, 2023 · The latest Atreca stock prices, stock quotes, news, and BCEL history to help you invest and trade smarter. ... The 11 analysts offering price forecasts for Atreca have a median target of 11.77 ... Competitors. Stock Price Forecast. The 1 analysts offering 12-month price forecasts for Ideanomics Inc have a median target of 30,387.50, with a high estimate of 30,387.50 and a low estimate of ...
The current Atreca [ BCEL] share price is $0.21. The Score for BCEL is 45, which is 10% below its historic median score of 50, and infers higher risk than normal. BCEL is currently trading in the 40-50% percentile range relative to its historical Stock Score levels.The above table shows the analyst BCEL forecast and predictions for the stock price in 12 month’s time. Date Share Price Average 1Y Price Target Dispersion High Low 1Y Actual price Analysts; Current: US$0.22View Tecnoglass Inc TGLS investment & stock information. Get the latest Tecnoglass Inc TGLS detailed stock quotes, stock data, Real-Time ECN, charts, stats and more.Instagram:https://instagram. first mining gold stock pricelargest investment firms in usaccredited america insurance reviewsrental property insurance california Aug 14, 2023 · BCEL Earnings Date and Information. Atreca last posted its quarterly earnings data on May 10th, 2023. The reported ($0.54) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.56) by $0.02. Atreca has generated ($2.18) earnings per share over the last year ( ($2.18) diluted earnings per share). dfemxbarron's subscription See Atreca, Inc. (BCEL) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades.BANQUE POUR LE COMMERCE EXTERIEUR LAO PUBLIC. Date: Previous day: Opening : Last: Change: Change (%) High: Low: Trading Volume (shr) Trading Value (LAK) top day trading companies Find the latest Atreca, Inc. (BCEL) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors.The average Adma Biologics stock price prediction forecasts a potential upside of 43.11% from the current ADMA share price of $3.96. What is ADMA's forecast return on equity (ROE) for 2023-2026? (NASDAQ: ADMA) forecast ROE is N/A, which is considered weak.